Long School of Medicine

Search

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms

A cancer diagnosis is always devastating and is especially overwhelming when the patient is a child. This is why the CURE Childhood Cancer Foundation is on a mission to advance research that will bring an end to childhood cancers. Recently, Raushan Kurmasheva, PhD, assistant professor at the Greehey Children’s Cancer Research Institute and Department of […]

Treatment access, improvements will reach both rural and urban communities The Texas Health and Human Services Commission has formally announced that Be Well Texas, an initiative of the Be Well Institute on Substance Use and Related Disorders at UT Health San Antonio, has been selected to lead a major expansion of opioid use disorder and recovery support services across […]

FOXM1 protein identified as key driver in immunotherapy resistance, unlocking new therapeutic avenues   For years, scientists have found the overexpression of a specific protein called FOXM1 in a wide range of cancers, including ovarian, breast and pediatric cancers. A recent study by scientists at The University of Texas Health Science Center at San Antonio […]

Jennifer Sharpe Potter, PhD, MPH, founding director of Be Well Texas, an initiative of the Be Well Institute on Substance Use and Related Disorders at UT Health San Antonio, and senior vice president for research, was quoted in this article.   Read More

Morningstar: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Benzinga: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Nasdaq: Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment